Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2003-9-16
pubmed:abstractText
We investigated the mechanism of hemolytic anemia detected in a repeated-dose toxicity study using cynomolgus monkeys that were treated with a humanized antibody drug. This drug was an IgG1 monoclonal antibody (MoAb) that binds to the human HM1.24 antigen named anti-HM1.24 MoAb. The presence of the HM1.24 antigen on the erythrocyte membranes and the erythrocyte agglutination following the addition of anti-HM1.24 MoAb was examined. In addition, an indirect Coombs' test, a hemolysis assay and the measurement of anti-single stranded-DNA antibodies were performed using test animal serum or plasma. The specific binding of FITC- and 125I-labeled anti-HM1.24 MoAb to the erythrocyte membrane was not observed. HM1.24 antigen was not identified on the erythrocyte membranes. However, a high concentration (more than 713 microg/mL) of anti-HM1.24 MoAb hemagglutinated the erythrocyte suspensions. The cause of this agglutination was unclear, but it is assumed that the non-specific binding and/or adhesion caused the direct agglutination. In the examination using test serum from the anemic monkeys, a positive reaction in the indirect Coombs' test was noted. Moreover, in these Coombs' test-positive animals, the production of anti-single stranded-DNA antibodies was sequentially increased. In the female monkey sacrificed in extremis due to severe anemia, an in vitro hemolytic reaction was detected attributable to complement activation. From these results, the hemolytic anemia detected in the repeated-dose toxicity study was diagnosed as a drug-induced autoimmune hemolytic anemia (AIHA) and the primary cause was assumed to be production of IgG class anti-erythrocyte autoantibodies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0388-1350
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
123-38
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:12974605-Anemia, Hemolytic, Autoimmune, pubmed-meshheading:12974605-Animals, pubmed-meshheading:12974605-Antibodies, Monoclonal, pubmed-meshheading:12974605-Antigens, Surface, pubmed-meshheading:12974605-Autoantibodies, pubmed-meshheading:12974605-Coombs' Test, pubmed-meshheading:12974605-DNA, Single-Stranded, pubmed-meshheading:12974605-Dose-Response Relationship, Drug, pubmed-meshheading:12974605-Erythrocyte Aggregation, pubmed-meshheading:12974605-Erythrocyte Membrane, pubmed-meshheading:12974605-Erythrocytes, pubmed-meshheading:12974605-Female, pubmed-meshheading:12974605-Flow Cytometry, pubmed-meshheading:12974605-Hemolysis, pubmed-meshheading:12974605-Immunoglobulin G, pubmed-meshheading:12974605-Macaca fascicularis, pubmed-meshheading:12974605-Male, pubmed-meshheading:12974605-Membrane Glycoproteins, pubmed-meshheading:12974605-Toxicity Tests
pubmed:year
2003
pubmed:articleTitle
Investigation of the mechanism of drug-induced autoimmune hemolytic anemia in cynomolgus monkeys elicited by a repeated-dose of a humanized monoclonal antibody drug.
pubmed:affiliation
Fuji Gotemba Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba-shi, Shizuoka, 412-8513, Japan.
pubmed:publicationType
Journal Article